Table 2.
Treatment and sustained virological response rates in various subgroups
|
Fischer’s exact test, two-sides P value |
|||||
| Treatment rate % | SVR % | Number | Treatment rate | SVR | |
| Total | 45.3 | 49.6 | 13 999 | ||
| Genotypes 1/4/5/6 | 41.4 | 42.7 | 9114 | < 0.0001 | < 0.0001 |
| Genotypes 2/3 | 52.7 | 59.8 | 4885 | ||
| Clinical setting | 63.9 | 49.8 | 1298 | < 0.0001 | NS |
| Private practice | 43.4 | 49.6 | 12 701 | ||
| Male | 47.2 | 47.9 | 8214 | < 0.0001 | < 0.01 |
| Female | 42.6 | 52.3 | 5785 | ||
| Age ≤ 56 yr | 49 | 51.3 | 11 497 | < 0.0001 | < 0.0001 |
| Age > 56 yr | 28.2 | 36.7 | 2502 | ||
| BMI ≤ 23 (kg/m2) | 44.3 | 51.8 | 4762 | < 0.01 | < 0.05 |
| BMI > 23 (kg/m2) | 46.9 | 48.6 | 8846 | ||
| No employment | 38.9 | 47.3 | 8113 | < 0.0001 | < 0.001 |
| Regular employment | 54.1 | 52 | 5886 | ||
| Bad German language skills | 47 | 52.5 | 824 | NS | NS |
| Good German language skills | 45.8 | 47.8 | 7565 | ||
| Migrants | 53.3 | 52.6 | 2663 | < 0.0001 | < 0.0001 |
| German natives | 41.7 | 45.4 | 5465 | ||
| Infection length ≤ 12.5 yr | 62.8 | 51.6 | 3639 | < 0.0001 | < 0.01 |
| Infection length > 12.5 yr | 37.2 | 48 | 3165 | ||
| Ultrasound not performed | 30.7 | 47.5 | 2568 | < 0.0001 | NS |
| Ultrasound performed | 48.6 | 50 | 11 431 | ||
| Liver biopsy not performed | 39.9 | 50.1 | 11 100 | < 0.0001 | NS |
| Liver biopsy performed | 66.1 | 48.5 | 2899 | ||
| Fibrosis scores F0-1 | 60.9 | 52.4 | 1766 | < 0.0001 | < 0.01 |
| Fibrosis scores F2-4 | 74.6 | 44.1 | 1017 | ||
| Clinical symptoms absent | 42.2 | 47.8 | 4430 | < 0.0001 | NS |
| Clinical symptoms present | 46.7 | 50.4 | 9569 | ||
| No concomitant disease | 55.7 | 51.8 | 6527 | < 0.0001 | < 0.0001 |
| At least one concomitant disease | 36.2 | 46.8 | 7472 | ||
| Psychiatric disease absent | 46.9 | 49.8 | 12 281 | < 0.0001 | NS |
| Psychiatric disease present | 34.1 | 48.4 | 864 | ||
| Active drug or alcohol abuse absent | 49.9 | 49.7 | 10 960 | < 0.0001 | NS |
| Active drug or alcohol abuse present | 28.7 | 49.4 | 3039 | ||
| HIV co-infection absent | 46.1 | 50 | 13 254 | < 0.0001 | < 0.01 |
| HIV co-infection present | 31.4 | 39.3 | 745 | ||
| Good quality-of-life | 43.8 | 49.5 | 11 348 | < 0.0001 | NS |
| Reduced quality-of-life | 51.8 | 50.1 | 2651 | ||
| ALT normal (< 50 U/L for men, < 30 U/L for women) | 34.8 | 50.8 | 3297 | < 0.0001 | NS |
| ALT elevated (U/L) | 49.6 | 49.7 | 10 105 | ||
| Thrombocytes ≥ 142 500 /μL | 48 | 51.6 | 11 284 | < 0.0001 | < 0.0001 |
| Thrombocytes < 142 500 /μL | 38.9 | 36.2 | 1816 | ||
| HCV-RNA ≤ 520 000 IU/mL | 45.4 | 54.8 | 6810 | < 0.0001 | < 0.0001 |
| HCV-RNA > 520 000 IU/mL | 49.7 | 43.3 | 5904 | ||
| No concomitant disease | 55.7 | 51.8 | 6527 | < 0.0001 | < 0.0001 |
| At least one concomitant disease | 36.2 | 46.8 | 7472 | ||
| HIV co-infection absent | 46.1 | 50 | 13 254 | < 0.0001 | < 0.01 |
| HIV co-infection present | 31.4 | 39.3 | 745 | ||
SVR: Sustained virological response; BMI: Body mass index; HIV: Human immunodeficiency virus; ALT: Alanine aminotransferase; HCV: Hepatitis C virus; NS: Not significant.